Prostacyclin Influences the Pressure Reactivity in Patients with Severe Traumatic Brain Injury Treated with an ICP-Targeted Therapy

Neurocritical Care

Volumn 22, Issue 1, 2015, Pages 26-33

  Koskinen, Lars Owe D ^a   Eklund, Anders ^a   Sundström, Nina ^a   Olivecrona, Magnus ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

ICP; Outcome; Pressure reactivity; Prostacyclin; Traumatic brain injury

Indexed keywords

ANTIHYPERTENSIVE AGENT; PROSTACYCLIN;

ADOLESCENT; ADULT; BLOOD PRESSURE; BRAIN INJURIES; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; INTRACRANIAL PRESSURE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN INJURIES; DOUBLE-BLIND METHOD; EPOPROSTENOL; FEMALE; HUMANS; INTRACRANIAL PRESSURE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939883558     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-014-0030-8     Document Type: Article

References (37)

1. Cold GE. Cerebral blood flow in acute head injury. The regulation of cerebral blood flow and metabolism during the acute phase of head injury, and its significance for therapy. Acta Neurochir Suppl (Wien). 1990;49:1–64.
2. Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg. 1995;83:949–62.
3. Asgeirsson B, Grande PO, Nordstrom CH. A new therapy of post-trauma brain oedema based on haemodynamic principles for brain volume regulation. Intensive Care Med. 1994;20:260–7.
4. Grande PO. The “Lund Concept” for the treatment of severe head trauma–physiological principles and clinical application. Intensive Care Med. 2006;32:1475–84.
5. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74:163–219.
6. FitzGerald GA, Friedman LA, Miyamori I, O’Grady J, Lewis PJ. A double blind placebo controlled crossover study of prostacyclin in man. Life Sci. 1979;25:665–72.
7. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663–5.
8. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18–20.
9. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc. 1979;38:66–71.
10. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300:1142–7.
11. Lundblad C, Grande PO, Bentzer P. Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclin. J Cereb Blood Flow Metab. 2008;28:367–76.
12. Grande PO, Moller AD, Nordstrom CH, Ungerstedt U. Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements. Acta Anaesthesiol Scand. 2000;44:886–94.
13. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009;26:1251–62.
14. Aries MJ, Czosnyka M, Budohoski KP, et al. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Crit Care Med. 2012;40:2456–63.
15. Howells T, Elf K, Jones PA, et al. Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma. J Neurosurg. 2005;102:311–7.
16. Steiner LA, Czosnyka M, Piechnik SK, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med. 2002;30:733–8.
17. Lang EW, Chesnut RM. A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic brain injury patients. Br J Neurosurg. 2000;14:117–26.
18. Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. J Neurol Neurosurg Psychiatry. 2004;75:813–21.
19. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. Effective ICP reduction by decompressive craniectomy in patients with severe traumatic brain injury treated by an ICP-targeted therapy. J Neurotrauma. 2007;24:927–35.
20. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15:573–85.
21. Moncada S, Vane JR. Prostacyclin and its clinical applications. Ann Clin Res. 1984;16:241–52.
22. Brandt L, Ljunggren B, Andersson KE, Hindfelt B, Uski T. Effects of indomethacin and prostacyclin on isolated human pial arteries contracted by CSF from patients with aneurysmal SAH. J Neurosurg. 1981;55:877–83.
23. Brandt L, Ljunggren B, Andersson KE, Hindfelt B, Uski T. Prostaglandin metabolism and prostacyclin in cerebral vasospasm. Gen Pharmacol. 1983;14:141–3.
24. Koskinen LO, Olivecrona M, Rodling-Wahlstrom M, Naredi S. Prostacyclin treatment normalises the MCA flow velocity in nimodipine-resistant cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study. Acta Neurochir (Wien). 2009;151:595–9; discussion 599.
25. Wahlström M, Olivecrona M, Ahlm C, et al. Effects of prostacyclin on the early inflammatory response in patients with traumatic brain injury: a randomised clinical study. SpringerPlus. 2014;3:98.
26. Kurihara J, Sahara T, Kato H. Protective effect of beraprost sodium, a new chemically stable prostacyclin analogue, against the deterioration of baroreceptor reflex following transient global cerebral ischaemia in dogs. Br J Pharmacol. 1990;99:91–6.
27. de Souza M, Bouskela E. Arteriolar diameter and spontaneous vasomotion: importance of potassium channels and nitric oxide. Microvasc Res. 2013;90:121–7.
28. Rosenkranz AC, Rauch BH, Doller A, et al. Regulation of human vascular protease-activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT). Mol Pharmacol. 2011;80:337–44.
29. Pickard JD. Role of prostaglandins and arachidonic acid derivatives in the coupling of cerebral blood flow to cerebral metabolism. J Cereb Blood Flow Metab. 1981;1:361–84.
30. Sviri GE, Aaslid R, Douville CM, Moore A, Newell DW. Time course for autoregulation recovery following severe traumatic brain injury. J Neurosurg. 2009;111:695–700.
31. Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41:11–7; discussion 17–9.
32. Jaeger M, Schuhmann MU, Soehle M, Meixensberger J. Continuous assessment of cerebrovascular autoregulation after traumatic brain injury using brain tissue oxygen pressure reactivity. Crit Care Med. 2006;34:1783–8.
33. Steiner LA, Pfister D, Strebel SP, Radolovich D, Smielewski P, Czosnyka M. Near-infrared spectroscopy can monitor dynamic cerebral autoregulation in adults. Neurocrit Care. 2009;10:122–8.
34. Zweifel C, Lavinio A, Steiner LA, et al. Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury. Neurosurg Focus. 2008;25:E2.
35. Sanchez-Porras R, Santos E, Czosnyka M, Zheng Z, Unterberg AW, Sakowitz OW. ‘Long’ pressure reactivity index (L-PRx) as a measure of autoregulation correlates with outcome in traumatic brain injury patients. Acta Neurochir (Wien). 2012;154:1575–81.
36. Kirkness CJ, Mitchell PH, Burr RL, Newell DW. Cerebral autoregulation and outcome in acute brain injury. Biol Res Nurs. 2001;2:175–85.
37. Shahsavari S, McKelvey T, Ritzen CE, Rydenhag B. Cerebrovascular mechanical properties and slow waves of intracranial pressure in TBI patients. IEEE Trans Biomed Eng. 2011;58:2072–82.